In 2008, IAVI established the Vaccine Design and Development Laboratory (DDL) to work on replicating viral vectors. DDL researchers are designing novel vaccine immunogens and viral vectors based on the vesicular stomatitis virus.
DDL scientists, based at the bioscience center (BioBAT) within the historic Brooklyn Army Terminal in New York, are actively involved in developing new viral vectors and immunogens, testing vaccine concepts in vivo, and developing assays to characterize vaccine candidates and the immune responses they induce. With its facilities and expertise, the DDL is able to conduct the rigorous applied research required to advance a promising experimental vaccine from the lab to a stage at which it can meet the regulatory agency guidance associated with production of a clinical trial candidate.
The DDL collaborates with investigators at the IAVI Neutralizing Antibody Center (NAC); the Center for Infectious Disease Research in Seattle; the Université Laval in Canada; the Government of Japan; the Ragon Institute of Massachusetts General Hospital, MIT and Harvard; and Scripps Research, among others. Work at the DDL is supported by the National Institutes of Health (NIH), the NIH National Institute of Allergy and Infectious Diseases (NIAID), the World Bank, and the Bill & Melinda Gates Foundation.